S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
BRTX · BioRestorative Therapies, Inc. Common Stock (NV)
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
BioRestorative Therapies Inc (BRTX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.53
-0.05
(-3.16%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.53
$1.53
$1.53
52-WEEK RANGE
$1.53
$1.28
$34.40
What's happening
- BRTX is down 3.16% today, trading at $1.53. — Live quote
- It's trading within 3% of its 52-week low ($1.28). (Finnhub fundamentals)
- Volume today (561) is well below its 3-month average of 26,100. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-2.40 actual vs. $-4.08 estimated (+41.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BRTX
-93.36%
vs S&P 500
-106.14%
1-YEAR RETURN
BRTX
-95.19%
vs S&P 500
-109.75%
6-MONTH RETURN
BRTX
-69.65%
3-MONTH RETURN
BRTX
-75.81%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-04-26 (Q1 2026)
$-2.40
Est. $-4.08
BEAT +41.2%
2026-01-26 (Q4 2025)
$-6.20
Est. $-7.55
BEAT +17.9%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.37
BEAT +10.1%
2025-07-26 (Q2 2025)
$-0.30
Est. $-0.39
BEAT +22.6%
Valuation Measures & Ratios
Enterprise Value4-$999.6K
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)5.90
Price / Book72.29
EV4 / Revenue-2.79
EV4 / EBITDA—
Profit Margin-3089.55%
Operating Margin-3975.00%
Return on Equity (ROE8)-423.84%
Return on Assets (ROA9)-193.30%
Avg Volume (3M)26,100
Quarterly history (5 periods)
| Measure | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 |
|---|---|---|---|---|---|
| Market cap | $98.8M | $267.0M | $294.0M | $307.0M | — |
| P/E | -7.49 | -22.02 | -22.41 | -24.21 | — |
| Price/Sales | 271.92 | 465.40 | 451.55 | 802.30 | — |
| Price/Book | 32.65 | 120.98 | 60.67 | 49.97 | — |
| EV/Revenue | 263.35 | 464.35 | 449.16 | 799.08 | — |
| ROE | -435.90% | -549.43% | -270.69% | -206.40% | — |
| ROA | -284.22% | -214.89% | -154.01% | -122.82% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short13,152
Change from Prior Settlement+13.52%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -7.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -3089.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -95.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BRTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.2K | $11.8K | $303.3K | $25.0K | $233.6K | $89.1K | $35.0K | $30.7K |
| Gross profit | $15.8K | $1.2K | $294.6K | $22.1K | $215.4K | $82.6K | $35.0K | $30.7K |
| Operating income | -$3.4M | -$3.7M | -$3.3M | -$4.8M | -$2.3M | -$2.5M | -$4.1M | -$3.1M |
| Net income | -$2.2M | -$3.0M | -$2.7M | -$5.3M | -$1.1M | -$4.0M | -$2.2M | $4.8M |
| EPS (diluted) | $-0.12 | $-0.33 | $-0.30 | $-0.64 | $-0.13 | $-0.50 | $-0.33 | $0.39 |
| EPS (basic) | $-0.12 | $-0.33 | $-0.30 | $-0.64 | $-0.13 | $-0.50 | $-0.33 | $1.04 |
| Operating margin | -$14.6K | -$31.4K | -$1.1K | -$19.2K | -$979 | -$2.8K | -$11.7K | -$10.1K |
| Net margin | -$9.3K | -$25.7K | -$876 | -$21.4K | -$467 | -$4.5K | -$6.4K | $15.5K |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $4.6M | $4.1M | $5.6M | $8.5M | $10.3M | $12.3M | $14.6M | $16.1M |
| Total liabilities | — | — | — | $3.7M | $4.2M | $3.7M | $4.6M | $5.3M |
| Stockholders' equity | $3.0M | $356.7K | $2.2M | $4.8M | $6.1M | $8.5M | $10.0M | $10.8M |
| Total current assets | $3.8M | $3.1M | $4.7M | $7.6M | $9.4M | $11.1M | $13.5M | $15.0M |
| Total current liabilities | $1.6M | $3.7M | $3.4M | $3.7M | $4.2M | $3.7M | $4.6M | $5.3M |
| Cash & equivalents | $3.1M | $1.5M | $602.4K | $1.6M | $1.2M | $547.9K | $1.5M | $2.3M |
| Marketable securities (current) | $479.4K | $1.4M | $3.9M | $5.8M | $7.9M | $10.2M | $11.6M | $12.4M |
| Accounts receivable | $13.3K | $15.5K | $13.4K | $15.0K | $25.0K | $188.4K | $165.0K | $27.4K |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $328.8K | $358.8K | $309.5K | $339.7K | $370.0K | $362.9K | $378.4K | $345.8K |
| Intangible assets | $511.8K | $534.2K | $556.6K | $579.1K | $601.5K | $623.9K | $646.4K | $668.8K |
| Accounts payable | $666.9K | $1.3M | $859.9K | $609.9K | $599.5K | $483.1K | $401.4K | $215.9K |
| Accrued liabilities | — | — | — | — | — | $744.5K | $682.2K | $447.6K |
| Deferred revenue (current) | — | — | — | — | $150.0K | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.5K | $887 | $797 | $797 | $750 | $692 | $692 | $692 |
| Retained earnings | -$172.1M | -$169.9M | -$166.7M | -$163.7M | -$161.0M | -$155.7M | -$154.0M | -$153.0M |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.8M | -$2.4M | -$2.9M | -$2.7M | -$2.8M | -$2.3M | -$1.7M | -$1.9M |
| Investing cash flow | $968.4K | $2.4M | $2.0M | $2.1M | $2.4M | $1.5M | $936.8K | $3.0M |
| Financing cash flow | $4.4M | $923.2K | -$49.3K | $888.1K | $1.1M | -$126.3K | $0 | -$12.8K |
| Free cash flow | — | -$2.5M | -$2.9M | -$2.7M | -$2.8M | -$2.4M | -$1.8M | -$1.9M |
| Capital expenditures | — | $79.7K | $0 | $0 | $36.4K | $12.4K | $58.5K | $35.3K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $290.2K | $447.9K | $399.9K | $468.7K | $2.0M | $175.6K | $284.2K | $324.3K |
| Change in accounts receivable | -$2.2K | $2.1K | -$1.6K | -$10.0K | -$163.4K | $23.4K | $137.6K | -$7.6K |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$682.0K | $482.5K | $230.2K | $10.4K | $116.4K | $81.7K | $185.5K | -$15.0K |
| Purchases of investments | $74.9K | $0 | $550.5K | $1.1M | $1.1M | $2.6M | $5.5M | $2.1M |
| Share repurchases | $0 | $0 | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $359.7K | $401.0K | $145.8K | $119.8K | $46.0K |
| Gross profit | $335.9K | $372.9K | $145.8K | — | — |
| Operating income | -$15.6M | -$11.6M | -$15.2M | -$19.0M | -$26.3M |
| Net income | -$14.2M | -$9.0M | -$10.4M | -$18.5M | -$44.3M |
| EPS (diluted) | $-1.58 | $-1.16 | $-2.47 | $-5.11 | — |
| EPS (basic) | $-1.58 | $-1.16 | $-2.47 | $-5.11 | $-37.30 |
| Operating margin | -$4.4K | -$2.9K | -$10.4K | -$15.8K | -$57.2K |
| Net margin | -$4.0K | -$2.2K | -$7.1K | -$15.4K | -$96.3K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $4.1M | $12.3M | $12.6M | $16.4M | $22.5M |
| Total liabilities | — | $3.7M | $2.6M | $602.6K | $856.5K |
| Stockholders' equity | $356.7K | $8.5M | $10.0M | $10.3M | $21.6M |
| Total current assets | $3.1M | $11.1M | $11.4M | $15.1M | $21.5M |
| Total current liabilities | $3.7M | $3.7M | $2.6M | $440.3K | $363.8K |
| Cash & equivalents | $1.5M | $547.9K | $884.4K | $1.7M | $21.0M |
| Marketable securities (current) | $1.4M | $10.2M | $10.2M | $13.0M | — |
| Accounts receivable | $15.5K | $188.4K | $19.3K | $16.0K | $5.0K |
| Inventory | — | — | — | — | — |
| Property, plant & equipment | $358.8K | $362.9K | $356.1K | $261.0K | $38.0K |
| Intangible assets | $534.2K | $623.9K | $713.7K | $803.4K | $589.7K |
| Accounts payable | $1.3M | $483.1K | $189.4K | $170.9K | $50.8K |
| Accrued liabilities | — | $744.5K | $711.7K | $130.1K | $135.0K |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | — | — | — | — | $250.0K |
| Common stock & paid-in capital | $887 | $692 | $471 | $369 | $353 |
| Retained earnings | -$169.9M | -$155.7M | -$146.7M | -$152.6M | -$134.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$8.2M | -$6.4M | -$5.9M | -$3.3M |
| Investing cash flow | $8.9M | $514.5K | $3.3M | -$13.4M | -$30.7K |
| Financing cash flow | $2.9M | $7.4M | $2.3M | — | $21.3M |
| Free cash flow | -$10.9M | -$8.3M | -$6.6M | -$6.2M | -$3.4M |
| Capital expenditures | $116.1K | $106.2K | $171.0K | $265.2K | $30.7K |
| Depreciation & amortization | — | — | — | $120.5K | $89.1K |
| Share-based compensation | $3.3M | $2.8M | $7.8M | $12.6M | $23.1M |
| Change in accounts receivable | -$172.9K | $169.1K | $3.3K | $11.0K | -$12.0K |
| Change in inventory | — | — | — | — | — |
| Change in accounts payable | $839.5K | $293.7K | $18.5K | $120.1K | -$68.0K |
| Purchases of investments | $2.7M | $20.9M | $17.5M | $22.5M | — |
| Share repurchases | $0 | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BRTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-09-14 to 2025-10-06
Recent transactions
- Most recent: Silva Francisco (VP of Research and Development) — Grant / award of 11,719 shares on 2025-10-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Silva Francisco | VP of Research and Development | Grant / award | 2025-10-06 | 11,719 |
| ALSTODT LANCE | President, CEO, COB | Grant / award | 2025-10-06 | 15,625 |
| Broadrick Dale | Reporting person | Open market sale | 2024-10-28 | 1,112 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-10-06 | Silva Francisco | VP of Research and Development | Grant / award | 11,719 | $1.60 |
| 2025-10-06 | ALSTODT LANCE | President, CEO, COB | Grant / award | 15,625 | $1.60 |
| 2024-10-28 | Broadrick Dale | Reporting person | Open market sale | 1,112 | $1.58 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:02 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-04 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-21 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-07-16 | 8-K | 2026-07-08 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-26 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-01 | 8-K | 2026-05-01 | View on SEC.gov → |
Recent news
Headlines about BRTX (BioRestorative Therapies, Inc. Common Stock (NV)). Links open the publisher — we don’t host full articles.
-
BioRestorative Therapies announces 1-for-20 reverse stock split
Seeking Alpha · 2026-09-02 -
BioRestorative Therapies Announces Reverse Stock Split
Yahoo Finance · 2026-09-02 -
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
Yahoo Finance · 2026-06-25 -
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
Yahoo Finance · 2026-06-18 -
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
Yahoo Finance · 2026-05-27 -
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
Yahoo Finance · 2026-05-26 -
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Yahoo Finance · 2026-05-14 -
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
Yahoo Finance · 2026-05-13
No headlines in this category right now — try “All”.